Perspectify News
13 minutes ago
Fresh news on health and wellness in China
Provided by AGP
AGP Picks
View all
Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Filter
Press releases
Publish your press release
2 hours ago
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
GlobeNewswire, Inc.
Post-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.
4 hours ago
Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
GlobeNewswire, Inc.
Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology...
10 hours ago
Pediatric Investigation Study Finds AI and Clinicians Together Improve Pediatric Diagnosis
EIN Presswire
Researchers show advanced AI models improve diagnostic accuracy and complement clinicians, especially in complex pediatric and rare disease cases BEIJING, CHINA, May 4, 2026 /EINPresswire.com/ -- Artificial intelligence (AI) is increasingly...
9 hours ago
SNU Eye Clinic Korea Leads Global Innovation in SMILE and ICL Surgery
EIN Presswire
Advancing vision correction through SMILE surgery and implantable lens procedures with global clinical expertise and innovation.
14 hours ago
AIM Congress Expands Global Investment Dialogue into China’s Greater Bay Area with Launch of AIM Talks China 2026 in Guangzhou
GlobeNewswire, Inc.
DUBAI, United Arab Emirates and GUANGZHOU, China, May 03, 2026 (GLOBE NEWSWIRE) -- AIM Congress, the world’s leading investment platform, continues to expand its footprint in China with the launch of AIM Talks 2026 in Guangzhou.
Apr. 30, 2026
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
GlobeNewswire, Inc.
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant...
Video Stories
Sign up for China Health Report.
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.
Explore More
